NO20051663L - Fremgangsmater for behandling av neurodegenerasjon - Google Patents

Fremgangsmater for behandling av neurodegenerasjon

Info

Publication number
NO20051663L
NO20051663L NO20051663A NO20051663A NO20051663L NO 20051663 L NO20051663 L NO 20051663L NO 20051663 A NO20051663 A NO 20051663A NO 20051663 A NO20051663 A NO 20051663A NO 20051663 L NO20051663 L NO 20051663L
Authority
NO
Norway
Prior art keywords
methods
treating neurodegeneration
disease
alpha
treating
Prior art date
Application number
NO20051663A
Other languages
English (en)
Inventor
Daniel W Gil
Larry A Wheeler
John E Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NO20051663L publication Critical patent/NO20051663L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives fremgangsmåter for forhindring eller retardering av degenereringen av neuroner. Det beskrives også fremgangsmåter for behandling av Aizheimers sykdom eller Parkinsons sykdom gjennom administreringen av selektive alfa 2B eller alfa 2B/2C reseptoragonister.
NO20051663A 2002-10-08 2005-04-04 Fremgangsmater for behandling av neurodegenerasjon NO20051663L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41704902P 2002-10-08 2002-10-08
PCT/US2003/031809 WO2004032913A1 (en) 2002-10-08 2003-10-07 Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration

Publications (1)

Publication Number Publication Date
NO20051663L true NO20051663L (no) 2005-05-31

Family

ID=32093954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051663A NO20051663L (no) 2002-10-08 2005-04-04 Fremgangsmater for behandling av neurodegenerasjon

Country Status (19)

Country Link
US (1) US20040138312A1 (no)
EP (1) EP1549305B1 (no)
JP (2) JP4724421B2 (no)
KR (1) KR20050050124A (no)
CN (1) CN100431536C (no)
AT (1) ATE429216T1 (no)
AU (2) AU2003282758A1 (no)
BR (1) BR0314540A (no)
CA (1) CA2501347A1 (no)
DE (1) DE60327335D1 (no)
ES (1) ES2322954T3 (no)
IL (1) IL167849A (no)
MX (1) MXPA05003664A (no)
NO (1) NO20051663L (no)
NZ (1) NZ539328A (no)
PL (1) PL216373B1 (no)
RU (1) RU2330649C2 (no)
WO (1) WO2004032913A1 (no)
ZA (1) ZA200502744B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645678A1 (en) * 2006-03-16 2007-09-20 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US20110160265A1 (en) * 2007-10-18 2011-06-30 Luhrs Lauren M B Method of treating motor disorders with alpha-2b adrenergic receptor agonists
WO2009052072A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US8455548B2 (en) 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US8183414B2 (en) * 2008-12-08 2012-05-22 Allergan, Inc. N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds as subtype selective modulators of ALPHA2B or ALPHA2B and ALPHA2C adrenoceptors
KR20190108104A (ko) 2016-12-31 2019-09-23 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
MX2020014000A (es) 2018-06-27 2021-06-15 Bioxcel Therapeutics Inc Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
AU2020316013A1 (en) 2019-07-19 2022-02-17 Arx, Llc Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
PT1036065E (pt) * 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
CA2402405C (en) * 2000-07-14 2008-02-12 Allergan Sales, Inc. Compositions containing alpha-2-adrenergic agonist components
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

Also Published As

Publication number Publication date
EP1549305B1 (en) 2009-04-22
DE60327335D1 (de) 2009-06-04
RU2005114504A (ru) 2005-10-27
IL167849A (en) 2011-04-28
JP4724421B2 (ja) 2011-07-13
KR20050050124A (ko) 2005-05-27
JP2011057700A (ja) 2011-03-24
US20040138312A1 (en) 2004-07-15
CA2501347A1 (en) 2004-04-22
WO2004032913A1 (en) 2004-04-22
EP1549305A1 (en) 2005-07-06
AU2009238370A1 (en) 2009-12-17
CN100431536C (zh) 2008-11-12
ES2322954T3 (es) 2009-07-02
RU2330649C2 (ru) 2008-08-10
PL376346A1 (en) 2005-12-27
HK1081880A1 (zh) 2006-05-26
NZ539328A (en) 2007-01-26
BR0314540A (pt) 2005-07-26
PL216373B1 (pl) 2014-03-31
AU2003282758A1 (en) 2004-05-04
ZA200502744B (en) 2006-02-22
AU2009238370B2 (en) 2011-07-21
CN1703213A (zh) 2005-11-30
JP2006504739A (ja) 2006-02-09
ATE429216T1 (de) 2009-05-15
MXPA05003664A (es) 2005-06-08

Similar Documents

Publication Publication Date Title
DK1377589T3 (da) Oxazolyl-pyrazolderivater som kinaseinhibitorer
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MXPA05014166A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
DE60215000D1 (de) DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
IS2564B (is) Heterófjölhringjaefnasambönd og notkun þeirra sem metabótrópísk mótlyf gegn glútamat viðtökum
MXPA04003103A (es) Derivados de bencimidazolidinona como agentes muscarinicos.
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
ATE479686T1 (de) Pyridopyrrolizin- und pyridoindolizinderivate
DK1656346T3 (da) 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
WO2006047032A3 (en) Indole compounds useful as serotonin selective agents
NO20051663L (no) Fremgangsmater for behandling av neurodegenerasjon
DE60227576D1 (de) 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
DK1220852T3 (da) Substituerede diazepaner
WO2003072572A8 (en) Beta3-adrenergic receptor agonists
NO20056116L (no) Tiowolframatanaloger og anvendelse av slike
DK1223930T3 (da) Behandling af dyskinesi
BR0314541A (pt) Tratamento de demência e doença de parkinson